Connect with:
Thursday / October 17. 2024

logo
mobile-logo
HomePosts Tagged "Lumpi-ProVacInd"
Agro Universities, Agrotech, Animal Health, India, R&D

Lumpi-ProVacind is jointly developed by ICAR-NRC Equines and ICAR-IVRI to Biovet Pvt. Ltd

Agrinnovate, the commercial arm of ICAR, granted a non-exclusive license to Biovet Pvt. Ltd.  “The effort put forth by Agrinnovate India is commendable” said Dr. Himanshu Pathak, Secretary (DARE) & Director General (ICAR) and Chairman, Agrinnovate India Limited (AgIn) during the “ICAR-National Research Centre on Equines, Hisar & ICAR-Indian Veterinary Research Institute, Izatnagar Lumpi-ProVacind Technology Transfer” event.

Agrinnovate India Limited (AgIn) grants “Non-Exclusive Rights” for Commercial production of “Lumpi-ProVacind” jointly developed by ICAR-NRC Equines and ICAR-IVRI to Biovet Pvt. Ltd.

Dr Pathak congratulated the Biovet Pvt. Ltd., ICAR-NRCE, ICAR-IVRI and AgIn for the successful transfer of the technology. He further elaborated this technology will definitely meet out the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease.

Dr. Bhupander Nath Tripathi, Deputy Director General (Animal Science) highlighted the relevance of the technology and said that the vaccine could help the company to start manufacturing as soon as possible so as to make the vaccine market ready for further dissemination to the farmers helping them to overcome the disease.

Dr. Sudha Mysore, CEO, Agrinnovate India Ltd. indicated that this technology transfer is a major game changer for AgIn, with this transfer AgIn’s gross turnover reaches Rs. 17 crores Since 2018-19.

Dr. Yash Pal, Director, ICAR-NRCE outlined the technical results of the technology Lumpi-ProVacind & field results are encouraging and Dr. Triveni Dutt, Director, ICAR-IVRI expressed gratitude to the council for timely support.

Dr. Sreenivasulu Kilari, Executive Director, Biovet Pvt. Ltd. mentioned that the organization is glad to avail the license for Lumpi-ProVacind and expressed that experience with Agrinnovate in the technology transfer process exceptional.

Lumpi-ProVacind is jointly developed by ICAR-NRC Equines

Animal Health, Dairy, India, Interaction, Live Stock, R&D, Uncategorized

Will it be of much significance to tackle the hazard at the earliest or will it take too long to reach the beneficiaries?

India has been wading through the menace of the Lumpy Skin Disease (LSD) which has currently killed about 57,000 bovines and infected around over 15.21 lakh cattle. The global concern was widely discussed during the recently held “World Dairy Summit 2022’, from 12th-15th September, with a host of speakers declaring it as a dairy exigency.

The discussion revolved around the recently launched vaccine- Lumpi-ProVacInd, an indigenous shot developed by the Indian Council of Agricultural Research (ICAR) that is currently awaiting a nod for emergency use from Department of Animal Husbandry & Dairying (DAHD) for the treatment of LSD. The delay is centred around the vaccine’s efficacy and its subsequent line of production.  Praveen Malik, Commissioner, Department of Animal Husbandry & Dairying (DAHD), talked to AgroSpectrum India highlighting similar concerns on the outlines of the global summit. He said, “The indigenous vaccine announced recently has been unnecessarily creating a buzz and wrongly termed as a breakthrough without even going through a pilot run. It needs to be properly tested before we can see any significant results on the ground in terms of preventing or curing the disease.” “After the requisite trials, it needs to be manufactured on a large scale to distribute it to all the stakeholders, not just a fraction of the population who need it. Else, the entire purpose of producing the vaccination will be defeated. Given this outlook, the bigger question is about the companies responsible for producing the vaccination at a later stage. Also, the entire process will take a significant time before we move the needle to the next stage,” he continued.

Union Agriculture Minister Narendra Singh Tomar, during the launch of the indigenous vaccine to protect livestock from the disease in August this year however shared a different outlook on the efficacy of the shot and called it a ‘milestone event’. He said that Indian scientists have undertaken limited trials in a short period and have developed a 100 per cent effective vaccine complying with all standards, which will be effective in getting rid of the disease.

During the summit, Malik also commented on the existing portfolio of vaccinations available including Goat Pox, which is the current shot being administered in India to treat the spread of the deadly disease. Elaborating on its use, Malik said, “Goat Pox has good efficacy to completely eradicate LSD from the ground in the time to come. With the continuous use of this product, India will be left with a marginal number of such cases in a month or less, just like the small number of Covid cases we see today. The vaccination also has an avoidable or no relapse rate, making it an effective remedy against the widespread disease.”

In August, around 1.53 crore cattle were vaccinated with Goat Pox with the government aiming to vaccinate the entire population in the days ahead. It is a heterologous vaccine, currently being manufactured by Hester Biosciences Ltd and Indian Immunologicals Ltd respectively.

Whether the new vaccine would help further in eradicating this disease completely, is something to be seen over time.

By Manishika Miglani

Image credit- shutterstock

Will it be of much significance to

AgroPolicy, Animal Health, India, Live Stock

Vaccine is made by National Equine Research Center in collaboration with Indian Veterinary Research Institute.

Providing a big relief to the livestock of the country, the Union Minister for Agriculture and Farmers Welfare, Narendra Singh Tomar, has launched the indigenous vaccine Lumpi-ProVacInd to protect livestock from Lumpy Skin disease. The vaccine has been developed by the National Equine Research Center, Hisar (Haryana) in collaboration with the Indian Veterinary Research Institute, Izzatnagar (Bareilly).

Describing this vaccine as a milestone for eradicating the Lumpy disease, Tomar said that livestock, along with human resource, is the biggest asset of our country, which we have a big responsibility to preserve and prosper.

Tomar said that yet another new dimension has been set by developing this vaccine under the Indian Council of Agricultural Research (ICAR). He congratulated the scientists of the Equine Research Center and the Veterinary Research Institute for developing the Lumpi disease vaccine. Ever since the disease came to India in 2019, research institutes have been engaged in developing the vaccine.

Tomar directed the concerned officials to provide this vaccine in large numbers at the earliest for relief to the cattle. He said that there are thirty crore livestock in the country, considering the plight of mute animals, all possible measures should be taken to provide them relief at the earliest.

Vaccine is made by National Equine Research